- Home
- WWR vs PMVP Comparison
WWR vs PMVP Comparison
Compare WWR & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWR | PMVP |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 66.1M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WWR | PMVP |
|---|---|---|
| Price | $0.56 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.92 | N/A |
| AVG Volume (30 Days) | ★ 862.8K | 682.9K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $1.02 |
| 52 Week High | $3.75 | $1.88 |
Technical Indicators
Market Signals| Indicator | WWR | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 62.68 |
| Support Level | $0.54 | $1.06 |
| Resistance Level | $0.57 | $1.88 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 47.18 | 93.77 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.